Epilepsy is one of the challenging medical conditions affecting neonates, children and elderly. It has affected 1710 to 9780/million populations within India. Although the report of this condition dates to the prehistoric era, drugs for its treatment are not 100% effective and more often lead to toxic effects. Therefore, a potent drug or a drug adjunct is the need-of-the-hour for providing effective control for this neurological condition. The aim of the present study is to evaluate lacidipine, a calcium channel blocker as a protective agent in seizures induced by standard models of epilepsy, namely maximal electroshock seizure model (MES) and Pentylenetetrazole (PTZ). Standard methods for the induction of seizures such as MES and PTZ were performed on male Wistar albino mice. The mice were then treated with vehicle/standard drug (sodium valproate)/ lacidipine. Further, the standard parameters of recovery duration were evaluated. The study revealed that lacidipine at a dose of 3mg/kg body weight significantly reduced the duration of hind limb tonic extension and postictal depression in MES. PTZ-induced seizures showed significantly reduced mean duration of hind limb tonic flexion, hind limb tonic extension, clonus and postictal depression. The findings from the present study suggest that lacidipine has potent anticonvulsant ability in better protection against MES-induced seizures over that of the PTZ-induced one.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.